期刊论文详细信息
American Journal of Translational Research
Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice
Ji Yang1  Wenjing Zhou2 
[1] Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China;Department of Geriatrics, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
关键词: AMP-activated protein kinase (AMPK);    fetuin B;    hepatic steatosis;    liver X receptor (LXR);    Non-alcoholic fatty liver disease (NAFLD);   
DOI  :  
学科分类:医学(综合)
来源: e-Century Publishing Corporation
PDF
【 摘 要 】

Previous findings supported that fetuin B, a new hepatokine, may be involved in the development of hepatic steatosis, but the mechanism is still unknown. This study aims to investigate the role of fetuin B in hepatic steatosis in C57BL/6 mice and HepG2 cells. 1) We found that the administration of recombinant fetuin B aggravated hepatic lipid accumulation caused by free fatty acids (FFAs) or high fat diet, in vivo and in vitro. It lowered the phosphorylated AMPK levels and activated the LXR-SREBP1c pathway, accompanied by the downregulation of fatty acid oxidation and upregulation of lipogenesis. Furthermore, in HepG2 cells exposed to recombinant fetuin B and FFAs, the AMPK agonist depressed the LXR-SREBP1c pathway and alleviated lipid accumulation. The knockdown of LXR protected against steatosis but failed to change phosphorylated AMPK. 2) The knockdown of fetuin B by siRNA or shRNA alleviated lipid accumulation, in vivo and in vitro. It enhanced phosphorylated AMPK and depressed the LXR-SREBP1c pathway, accompanied by upregulation of fatty acid oxidation and downregulation of lipogenesis. Moreover, in HepG2 cells exposed to fetuin B siRNA and FFAs, LXR agonist aggravated lipid accumulation but failed to influence AMPK. This study indicated that fetuin B aggravated LXR-mediated hepatic steatosis through AMPK. It might offer new insights into clinical management and biomarker research on fatty liver.

【 授权许可】

CC BY-NC   

【 预 览 】
附件列表
Files Size Format View
RO201910256478071ZK.pdf 1781KB PDF download
  文献评价指标  
  下载次数:34次 浏览次数:11次